Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here
Check out our latest white paper! We partnered with Informa Pharma Intelligence to bring you the latest information on COVID-19 and its effect on the clinical landscape.
Rare disease drug development varies from the pathways seen in more established indications. The sample sizes are often...
Systemic lupus erythematosus is an autoimmune disease that presents differently in each person. There are roughly 150 people...
Tags: Pharm-Olam Insights, Autoimmune
The COVID-19 Pandemic continues to evolve and fluctuate across the globe – but not evenly or predictably. Some countries have...
Tags: Pharm-Olam Insights, Infectious Disease & Vaccines, Investigator Insights,
In rare disease, every patient matters and it is important for CRO and sponsor medical staff to effectively monitor and...
The United Kingdom officially withdrew from the European Union (EU) on Jan 31, 2020. They have until Dec 31, 2020 to complete...
Pharm-Olam, as a global CRO, has over 20 years' experience conducting clinical trials in Central and Eastern Europe (CEE). In...
Pharm-Olam is an allergy focused CRO and have worked on over 35 allergy clinical trials. In this article, we explore the area...
Effective Data management plays a critical role in the conduct of clinical trials. Clinical research requires quality data...
Subscribe to our blog and we'll give you our GDPR Controller & Processor Checklist.
